HCPCS Level II code J2508 designates the injectable biologic pegunigalsidase alfa-iwxj, billed per 1 mg unit. This code is used for administration of an enzyme replacement therapy delivered intravenously for patients requiring this specific biologic agent. Nationally, accurate use of J2508 affects payment, prior authorization workflows, and access to specialty infusion services for medically indicated patients.

Key payers covered in this publication include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for this enzyme replacement product, typical sites of service where it is administered, and the coding conventions that drive claims processing. The publication provides benchmarking information where available, summarizes relevant policy and coverage considerations from major payers, and outlines billing considerations specific to a per-milligram HCPCS Level II injectable code.

This analysis is intended for a national audience of coding professionals, revenue cycle managers, and specialty clinicians. It highlights billing and documentation implications tied to unit-based reporting, common places-of-service for infusion therapies, and areas where payer policies commonly affect authorization and reimbursement outcomes.